{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:58:28Z","timestamp":1761101908889,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.bcmd.2010.05.001","type":"journal-article","created":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T04:47:04Z","timestamp":1276145224000},"page":"111-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply"],"prefix":"10.1016","volume":"46","author":[{"given":"Ari","family":"Zimran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gheona","family":"Altarescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Elstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2010.05.001_bb0005","first-page":"3635","article-title":"Gaucher disease","volume":"Vol III","author":"Beutler","year":"2001"},{"key":"10.1016\/j.bcmd.2010.05.001_bb0010","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0020","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0140-6736(95)91038-7","article-title":"Replacement therapy with imiglucerase for type 1 Gaucher's disease","volume":"345","author":"Zimran","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2010.05.001_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(94)90042-6","article-title":"Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype and clinical features on response to treatment","volume":"97","author":"Zimran","year":"1994","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0030","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/qjmed\/91.7.483","article-title":"Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease","volume":"91","author":"Elstein","year":"1998","journal-title":"Q. J. Med."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1006\/bcmd.2000.0311","article-title":"Dosage-response in the treatment of Gaucher disease by enzyme replacement therapy","volume":"26","author":"Beutler","year":"2000","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0040","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","article-title":"Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis","volume":"108","author":"de Fost","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2010.05.001_bb0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","article-title":"Dose\u2013response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1","volume":"11","author":"Grabowski","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0050","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2010.05.001_bb0055","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1365-2141.2000.02177.x","article-title":"Withdrawal of enzyme replacement therapy in Gaucher disease","volume":"110","author":"Elstein","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0060","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00125817-200211000-00005","article-title":"Cessation of enzyme replacement therapy in Gaucher disease","volume":"4","author":"Grinzaid","year":"2002","journal-title":"Genet. Med."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0065","first-page":"127","article-title":"Extended interval between enzyme therapy infusions for adult patients with Gaucher's disease type 1","volume":"49","author":"P\u00e9rez-Calvo","year":"2003","journal-title":"J. Postgrad. Med."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0070","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMp0906922","article-title":"Drug shortages and public health shortages","volume":"361","author":"Steinbrook","year":"2009","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0075","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcmd.2009.12.002","article-title":"Guidelines for the restart of imiglucerase in patients with Gaucher disease: recommendations from the European Working Group on Gaucher disease","volume":"44","author":"Hollak","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0080","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(89)90536-9","article-title":"Prediction of severity of Gaucher's disease by identification of mutations at DNA level","volume":"2","author":"Zimran","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2010.05.001_bb0085","first-page":"565","article-title":"Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy","volume":"86","author":"Zevin","year":"1993","journal-title":"Q. J. Med."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0090","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0095","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.21280","article-title":"A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bcmd.2009.12.001","article-title":"Recommendations for treating patients with Gaucher disease with emerging enzyme products","volume":"44","author":"Cox","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2010.05.001_bb0105","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","article-title":"Phase I \/II and extension study of velaglucerase alfa (Gene-Activated\u2122 Human Glucocerebrosidase) replacement therapy in adults with type 1 Gaucher disease: 48 month experience","volume":"115","author":"Zimran","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2010.05.001_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2009.10.026","article-title":"Novel enzyme replacement therapy for Gaucher disease: phase III pivotal clinical trial with plant cell expressed recombinant glucocerebrosidase (prGCD)- taliglucerase alpha","author":"Aviezer","year":"2010"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979610001245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979610001245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:28:05Z","timestamp":1761049685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979610001245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1079979610001245"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2010.05.001","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2010.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}